✦ LIBER ✦

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

✍ Scribed by Norman R. Relkin; Paul Szabo; Basia Adamiak; Tuna Burgut; Carmen Monthe; Richard W. Lent; Steven Younkin; Linda Younkin; Richard Schiff; Marc E. Weksler

Book ID: 116781271
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 523 KB
Volume: 30
Category: Article
ISSN: 0197-4580
DOI: 10.1016/j.neurobiolaging.2007.12.021

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P4-351: Effects of uninterrrupted intrav

P4-351: Effects of uninterrrupted intravenous immunoglobulin treatment of Alzheimer's disease for nine months

✍ Tsakanikas, Diamanto; Shah, Kavita; Flores, Carolina; Assuras, Stephanie; Relkin 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Clinical Trials of Intravenous Immunoglo

Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease

✍ Relkin, Norman 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 270 KB

Intravenous immunoglobulin for the treat

Intravenous immunoglobulin for the treatment of Crohn's disease

✍ Rogosnitzky, Moshe; Danks, Rachel; Holt, Daniel 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 333 KB

Results of the GAP 160701 study: A phase

Results of the GAP 160701 study: A phase 3 clinical trial of intravenous immunoglobulin for mild-to-moderate Alzheimer's disease

✍ Relkin, Norman 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Drug-ranging study of intravenous immuno

Drug-ranging study of intravenous immunoglobulin in patients with Alzheimer’s disease

✍ Marc Weksler; Paul Szabo; Carmen Monthé; Laura Salvatierra; Stephen Younkin; Lin 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Intravenous immunoglobulin for treatment

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

✍ Dodel, Richard; Rominger, Axel; Bartenstein, Peter; Barkhof, Frederik; Blennow, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 746 KB